- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase <scp>I</scp>/<scp>II</scp> open‐label, dose escalation study
-
- Sophie Cousin
- Medical Oncology Department Institut Bergonié Bordeaux France
-
- Jean‐Yves Blay
- Medical Oncology Department Centre Léon Bérard Lyon France
-
- Irene Braña Garcia
- Medical Oncology Department Vall d'Hebron University Hospital, Vall d'Hebron Institut of Oncology (VHIO) Barcelona Spain
-
- Johann S. de Bono
- The Institute of Cancer Research and Royal Marsden Hospital London UK
-
- Christophe Le Tourneau
- Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit Institut Curie, Paris‐Saclay University Paris and Saint‐Cloud France
-
- Victor Moreno
- Medical Oncology, START Madrid‐FJD Fundación Jiménez Díaz Hospital Madrid Spain
-
- Jose Trigo
- Medical Oncology Department Hospital Universitario Virgen de la Victoria y Regional, IBIMA Málaga Spain
-
- Christine L. Hann
- Johns Hopkins University School of Medicine Baltimore Maryland USA
-
- Arun A. Azad
- Peter MacCallum Cancer Centre Victoria Australia
-
- Seock‐Ah Im
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine Seoul Republic of Korea
-
- Philippe A. Cassier
- Medical Oncology Department Centre Léon Bérard Lyon France
-
- Christopher A. French
- Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA
-
- Antoine Italiano
- Early Phase Trials and Sarcoma Units Institut Bergonié Bordeaux France
-
- Vicki L. Keedy
- Department of Medicine, Hematology and Oncology Vanderbilt‐Ingram Cancer Center Nashville Tennessee USA
-
- Ruth Plummer
- Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK
-
- Marie‐Paule Sablin
- Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit Institut Curie, Paris‐Saclay University Paris and Saint‐Cloud France
-
- Matthew L. Hemming
- Department of Medical Oncology, Dana‐Farber Cancer Institute and Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
-
- Geraldine Ferron‐Brady
- GSK Collegeville Pennsylvania USA
-
- Anastasia Wyce
- GSK Collegeville Pennsylvania USA
-
- Ahmed Khaled
- GSK Collegeville Pennsylvania USA
-
- Antara Datta
- GSK Collegeville Pennsylvania USA
-
- Shawn W. Foley
- GSK Collegeville Pennsylvania USA
-
- Michael T. McCabe
- GSK Collegeville Pennsylvania USA
-
- Yuehui Wu
- GSK Collegeville Pennsylvania USA
-
- Thierry Horner
- GSK Collegeville Pennsylvania USA
-
- Brandon E. Kremer
- GSK Collegeville Pennsylvania USA
-
- Arindam Dhar
- GSK Collegeville Pennsylvania USA
-
- Peter J. O'Dwyer
- Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania USA
-
- Geoffrey I. Shapiro
- Department of Medical Oncology, Dana‐Farber Cancer Institute and Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
-
- Sarina A. Piha‐Paul
- Department of Investigational Cancer Therapeutics University of Texas MD Anderson Cancer Center Houston Texas USA
Search this article
Description
<jats:title>Abstract</jats:title><jats:p>Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the recommended Phase 2 dose (RP2D). Here we present the results of Part 2 of our study, investigating safety, pharmacokinetics, pharmacodynamics and clinical activity of molibresib at the RP2D for nuclear protein in testis carcinoma (NC), small cell lung cancer, castration‐resistant prostate cancer (CRPC), triple‐negative breast cancer, estrogen receptor‐positive breast cancer and gastrointestinal stromal tumor. The primary safety endpoints were incidence of adverse events (AEs) and serious AEs; the primary efficacy endpoint was overall response rate. Secondary endpoints included plasma concentrations and gene set enrichment analysis (GSEA). Molibresib 75 mg once daily demonstrated no unexpected toxicities. The most common treatment‐related AEs (any grade) were thrombocytopenia (64%), nausea (43%) and decreased appetite (37%); 83% of patients required dose interruptions and 29% required dose reductions due to AEs. Antitumor activity was observed in NC and CRPC (one confirmed partial response each, with observed reductions in tumor size), although predefined clinically meaningful response rates were not met for any tumor type. Total active moiety median plasma concentrations after single and repeated administration were similar across tumor cohorts. GSEA revealed that gene expression changes with molibresib varied by patient, response status and tumor type. Investigations into combinatorial approaches that use BET inhibition to eliminate resistance to other targeted therapies are warranted.</jats:p>
Journal
-
- International Journal of Cancer
-
International Journal of Cancer 150 (6), 993-1006, 2021-11-26
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360017286857635712
-
- ISSN
- 10970215
- 00207136
-
- Data Source
-
- Crossref